Athira Pharma (ATHA)
(Delayed Data from NSDQ)
$1.92 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ATHA 1.92 0.00(0.00%)
Will ATHA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATHA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATHA
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
ATHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
Other News for ATHA
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Athira Pharma appoints Javier San Martin as Chief Medical Officer
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma announces publication of preclinical data on fosgonimeton
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting